Graft-versus-host disease risk factors: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
m (Bot: Removing from Primary care) |
||
(4 intermediate revisions by 2 users not shown) | |||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The | The most potent risk factor for GvHD is disparity in [[Human leukocyte antigen|HLA alleles]] between the recipient and donor. Some risk factors depend on demographics of the recipient and donor. | ||
==Risk Factors== | ==Risk Factors== | ||
Risk factors for GvHD include: | Risk factors for GvHD include: | ||
*High degree of HLA disparity between host and donor cells<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | *High degree of [[HLA]] disparity between host and donor cells<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | ||
*Use of unrelated donors as the stem cell source<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | *Use of unrelated donors as the [[stem cell]] source<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | ||
*Total body irradiation as the conditioning regimen prior to transplant<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | *[[Total body irradiation]] as the conditioning regimen prior to transplant<ref name="pmid22770714">{{cite journal| author=Rezvani AR, Storb RF| title=Prevention of graft-vs.-host disease. | journal=Expert Opin Pharmacother | year= 2012 | volume= 13 | issue= 12 | pages= 1737-50 | pmid=22770714 | doi=10.1517/14656566.2012.703652 | pmc=3509175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22770714 }} </ref> | ||
*Prior acute GvHD<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | *Prior acute GvHD<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
*Use of peripheral blood stem cells<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | *Use of peripheral blood [[stem cells]]<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
*Use of a T | *Use of a [[T cell]] replete graft<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
*Viral infection, since this can contribute to immune activation<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | *Viral infection, since this can contribute to immune activation<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
*Male host<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | *Male host<ref name="pmid24914139">{{cite journal| author=Socié G, Ritz J| title=Current issues in chronic graft-versus-host disease. | journal=Blood | year= 2014 | volume= 124 | issue= 3 | pages= 374-84 | pmid=24914139 | doi=10.1182/blood-2014-01-514752 | pmc=4102710 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24914139 }} </ref> | ||
Line 21: | Line 21: | ||
Protective | Protective factors include: | ||
*High degree of HLA concordance between the host and donor | *High degree of [[HLA]] concordance between the host and donor | ||
*Use of umbilical cord blood as the donor source (given decreased number of donor T cells) | *Use of [[umbilical cord blood]] as the donor source (given decreased number of donor [[T cells]]) | ||
==References== | ==References== | ||
Line 31: | Line 31: | ||
{{WH}} | {{WH}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Immunology]] | [[Category:Immunology]] |
Latest revision as of 21:56, 29 July 2020
Graft-versus-host disease |
Differentiating Graft-versus-host disease from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Graft-versus-host disease risk factors On the Web |
American Roentgen Ray Society Images of Graft-versus-host disease risk factors |
Risk calculators and risk factors for Graft-versus-host disease risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
The most potent risk factor for GvHD is disparity in HLA alleles between the recipient and donor. Some risk factors depend on demographics of the recipient and donor.
Risk Factors
Risk factors for GvHD include:
- High degree of HLA disparity between host and donor cells[1]
- Use of unrelated donors as the stem cell source[1]
- Total body irradiation as the conditioning regimen prior to transplant[1]
- Prior acute GvHD[2]
- Use of peripheral blood stem cells[2]
- Use of a T cell replete graft[2]
- Viral infection, since this can contribute to immune activation[2]
- Male host[2]
- Multiparous female donor[2]
Protective factors include:
- High degree of HLA concordance between the host and donor
- Use of umbilical cord blood as the donor source (given decreased number of donor T cells)
References
- ↑ 1.0 1.1 1.2 Rezvani AR, Storb RF (2012). "Prevention of graft-vs.-host disease". Expert Opin Pharmacother. 13 (12): 1737–50. doi:10.1517/14656566.2012.703652. PMC 3509175. PMID 22770714.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Socié G, Ritz J (2014). "Current issues in chronic graft-versus-host disease". Blood. 124 (3): 374–84. doi:10.1182/blood-2014-01-514752. PMC 4102710. PMID 24914139.